Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumors

Giuseppe Curigliano • 28 May 2020
ASCO 2020
General Lung Cancer Non-Small Cell Lung Cancer Thyroid Cancer Pralsetinib
ARROW

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, gives an overview of the ARROW study (NCT03037385), which was designed to evaluate the safety, tolerability and preliminary antineoplastic activity of pralsetinib in patients with medullary thyroid cancer, RET-altered non-small cell lung cancer (NSCLC) and other RET-altered solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Giuseppe Curigliano

6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
2:49
PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe
Giuseppe Curigliano • 9 Dec 2021
2:52
Future research directions for breast cancer
Giuseppe Curigliano • 9 Dec 2021
1:51
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano • 25 Mar 2021

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals